Market News
Monday, January 23, 2017
BRIEF-NantKwest says FDA authorized co's IND for early-stage study
* NantKwest - U.S. FDA has authorized co's IND for its
first-in-human, high-affinity natural killer (haNK) cell therapy
Phase I clinical study
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment